Thus, mutations in the MAX gene appear to be rare and are unlikely to be associated with elevated tumor aggressiveness, making them unsuitable as targets of genetic screening for paragangliomas/pheochromocytomas. The gene discussed is MAX; the disease is paraganglioma.